ABSTRACT
Abstract The frequency of the use of drugs that act on the epidermal growth factor receptor (EGFR) is increasing, with the consequent onset of cutaneous toxicity, specifically acneiform eruption. The authors extensively review the topic, focusing on describing how these drugs can affect the skin and its appendages, that is, the pathophysiology that encompasses the cutaneous toxicity related to the use of EGFR inhibitors. In addition, it was possible to list the risk factors that may be associated with adverse effects of these drugs. Based on this recent knowledge, the authors expect to aid in the management of patients who are more vulnerable to toxicity, reduce morbidities, and improve the quality of life of patients undergoing treatment with EGFR inhibitors. Other issues related to the toxicity of EGFR inhibitors, such as the clinical aspects of the acneiform eruption grades, and other different types of cutaneous and mucosal reactions, are also included in the article.
ABSTRACT
The frequency of the use of drugs that act on the epidermal growth factor receptor (EGFR) is increasing, with the consequent onset of cutaneous toxicity, specifically acneiform eruption. The authors extensively review the topic, focusing on describing how these drugs can affect the skin and its appendages, that is, the pathophysiology that encompasses the cutaneous toxicity related to the use of EGFR inhibitors. In addition, it was possible to list the risk factors that may be associated with adverse effects of these drugs. Based on this recent knowledge, the authors expect to aid in the management of patients who are more vulnerable to toxicity, reduce morbidities, and improve the quality of life of patients undergoing treatment with EGFR inhibitors. Other issues related to the toxicity of EGFR inhibitors, such as the clinical aspects of the acneiform eruption grades, and other different types of cutaneous and mucosal reactions, are also included in the article.
Subject(s)
Acneiform Eruptions , Antineoplastic Agents , Drug-Related Side Effects and Adverse Reactions , ErbB Receptors , Humans , Acneiform Eruptions/chemically induced , Acneiform Eruptions/drug therapy , Antineoplastic Agents/adverse effects , Biomarkers , ErbB Receptors/antagonists & inhibitors , Quality of Life , Risk FactorsABSTRACT
Patients with psychocutaneous disorders often refuse psychiatric intervention in their first consultations, leaving initial management to the dermatologist. The use of psychotropic agents in dermatological practice, represented by antidepressants, antipsychotics, anxiolytics, and mood stabilizers, should be indicated so that patients receive the most suitable treatment rapidly. It is important for dermatologists to be familiar with the most commonly used drugs for the best management of psychiatric symptoms associated with dermatoses, as well as to manage dermatologic symptoms triggered by psychiatric disorders.
Subject(s)
Mental Disorders/drug therapy , Psychophysiologic Disorders/drug therapy , Psychotropic Drugs/therapeutic use , Skin Diseases/drug therapy , Skin Diseases/psychology , Dermatology , Female , Humans , Male , Risk FactorsABSTRACT
Abstract Patients with psychocutaneous disorders often refuse psychiatric intervention in their first consultations, leaving initial management to the dermatologist. The use of psychotropic agents in dermatological practice, represented by antidepressants, antipsychotics, anxiolytics, and mood stabilizers, should be indicated so that patients receive the most suitable treatment rapidly. It is important for dermatologists to be familiar with the most commonly used drugs for the best management of psychiatric symptoms associated with dermatoses, as well as to manage dermatologic symptoms triggered by psychiatric disorders.
Subject(s)
Humans , Male , Female , Psychophysiologic Disorders/drug therapy , Psychotropic Drugs/therapeutic use , Skin Diseases/psychology , Skin Diseases/drug therapy , Mental Disorders/drug therapy , Risk Factors , DermatologyABSTRACT
We report a case of phaeohyphomycosis that affected the leg of a 45-year-old Brazilian man, car mechanic and renal transplanted. The direct mycological examination evidenced dematiaceous septated hyphae. The pathogenic fungal species was identified as Exophiala xenobiotica. Antifungal activity in vitro revealed terbinafine as the best antifungal. For treatment, it was chosen surgical excision of the entire lesion and used systemic itraconazole. Phaeohyphomycosis caused by Exophiala xenobiotica is extremely rare and is closely related to transplant patients.
Subject(s)
Eosinophilia/pathology , Panniculitis/pathology , Toxocara canis/isolation & purification , Toxocariasis/microbiology , Animals , Buttocks , Child, Preschool , Eosinophilia/complications , Female , Humans , Panniculitis/complications , Skin/pathology , Toxocariasis/complications , Toxocariasis/diagnosisSubject(s)
Humans , Animals , Female , Child, Preschool , Child , Panniculitis/pathology , Toxocariasis/microbiology , Toxocara canis/isolation & purification , Eosinophilia/pathology , Skin/pathology , Buttocks , Panniculitis/complications , Toxocariasis/complications , Toxocariasis/diagnosis , Eosinophilia/complicationsABSTRACT
Incontinentia pigmenti is a rare genodermatosis in which the skin involvement occurs in all patients. Additionally, other ectodermal tissues may be affected, such as the central nervous system, eyes, hair, nails and teeth. The disease has a X-linked dominant inheritance pattern and is usually lethal to male fetuses. The dermatological findings occur in four successive phases, following the lines of Blaschko: First phase - vesicles on an erythematous base; second phase - verrucous hyperkeratotic lesions; third phase - hyperchromic spots and fourth phase - hypochromic atrophic lesions.
Subject(s)
Incontinentia Pigmenti/pathology , Skin/pathology , Alopecia/etiology , Alopecia/pathology , Cataract/etiology , Cataract/pathology , Central Nervous System Diseases/pathology , Humans , Incontinentia Pigmenti/complications , Male , Mutation , Tooth Abnormalities/etiology , Tooth Abnormalities/pathologyABSTRACT
Incontinentia pigmenti is a rare genodermatosis in which the skin involvement occurs in all patients. Additionally, other ectodermal tissues may be affected, such as the central nervous system, eyes, hair, nails and teeth. The disease has a X-linked dominant inheritance pattern and is usually lethal to male fetuses. The dermatological findings occur in four successive phases, following the lines of Blaschko: First phase - vesicles on an erythematous base; second phase - verrucous hyperkeratotic lesions; third phase - hyperchromic spots and fourth phase - hypochromic atrophic lesions.
